Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets (Unaudited)

v3.24.3
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents [note 6] $ 9,544 $ 15,546
Short-term investments [note 6] 33,367  
Grant receivable [note 3]   111
Prepaid expenses and other assets 2,618 1,325
Total current assets 45,529 16,982
Other assets and restricted cash [note 6] 304 92
Right-of-use assets [note 9] 20 66
License agreement [note 4 and note 5] 1,030 1,197
Goodwill 1,034 1,034
Total assets 47,917 19,371
Current liabilities:    
Accounts payable 1,011 618
Accrued liabilities other 898 351
Contingent consideration [note 5 and note 6] 699 528
Accrued clinical liabilities 1,745 280
Accrued compensation 2,341 2,311
Current portion of long-term obligations [note 9] 22 63
Current portion of convertible debt [note 6 and note 7]   16,662
Total current liabilities 6,716 20,813
Non-current portion of convertible debt [note 6 and note 7] 9,823  
Long-term obligations [note 9]   6
Total liabilities 16,539 20,819
Commitments and contingencies [note 9]
Stockholders' equity:    
Common stock, $0.001 par value, 150,000,000 shares authorized, 34,389,946 issued and outstanding at September 30, 2024 and 21,165,760 issued and outstanding at December 31, 2023 103 90
Additional paid-in capital 224,418 164,209
Accumulated deficit (193,218) (165,751)
Accumulated other comprehensive income 75 4
Total stockholders' equity 31,378 (1,448)
Total liabilities and stockholders' equity 47,917 19,371
Series A Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value
Series B Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value